NCT02640482View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

February 28, 2017

Conditions
Chronic Hepatitis C Virus (HCV) Infection
Interventions
DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

DRUG

Placebo for ABT-493/ABT-530

tablet

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY